- Home
- CCG vs KZIA Comparison
CCG vs KZIA Comparison
Compare CCG & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCG | KZIA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.5M | 74.4M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | CCG | KZIA |
|---|---|---|
| Price | $0.79 | $5.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $350.00 | $17.67 |
| AVG Volume (30 Days) | 90.1K | ★ 240.1K |
| Earning Date | 03-30-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $444,290,042.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $2.86 |
| 52 Week High | $1.54 | $17.40 |
Technical Indicators
Market Signals| Indicator | CCG | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 40.69 |
| Support Level | $0.78 | $5.28 |
| Resistance Level | $0.83 | $6.53 |
| Average True Range (ATR) | 0.03 | 0.76 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 18.70 | 27.71 |
Price Performance
Historical ComparisonAbout CCG Cheche Group Inc.
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services and other services in China.. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.